| Autor: |
Joo Yeon Lee, Garnett, Christine E., Gobburu, Jogarao V. S., Bhattaram, Venkatesh A., Brar, Satjit, Earp, Justin C., Jadhav, Pravin R., Krudys, Kevin, Lesko, Lawrence J., Fang Li, Jiang Liu, Madabushi, Rajnikanth, Marathe, Anshu, Mehrotra, Nitin, Tornoe, Christoffer, Yaning Wang, Hao Zhu |
| Předmět: |
|
| Zdroj: |
Clinical Pharmacokinetics; 2011, Vol. 50 Issue 10, p627-635, 9p |
| Abstrakt: |
Pharmacometric analyses have become an increasingly important component of New Drug Application (NDA) and Biological License Application (BLA) submissions to the US FDA to support drug approval, labelling and trial design decisions. Pharmacometrics is defined as a science that quantifies drug, disease and trial information to aid drug development, therapeutic decisions and/or regulatory decisions. In this report, we present the results of a survey evaluating the impact of pharmacometric analyses on regulatory decisions for 198 submissions during the period from 2000 to 2008. Pharmacometric review of NDAs included independent, quantitative analyses by FDA pharmacometricians, even when such analysis was not conducted by the sponsor, as well as evaluation of the sponsor's report. During 2000-2008, the number of reviews with pharmacometric analyses increased dramatically and the number of reviews with an impact on approval and labelling also increased in a similar fashion. We also present the impact of pharmacometric analyses on selection of paediatric dosing regimens, approval of regimens that had not been directly studied in clinical trials and provision of evidence of effectiveness to support a single pivotal trial. Case studies are presented to better illustrate the role of pharmacometric analyses in regulatory decision making. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink